Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Related Stories
Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 5 months
KRAS vaccine shows safety and durable immune responses in high-risk individuals / 6 wks
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 2 months
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 2 months
New drug doubles one-year survival in metastatic pancreatic cancer / 4 months
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 11 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Long COVID, Diagnostics, Animal Health, Medicaid and look for the RSS link.
StackHealth Time Machine